Skip to main content
Premium Trial:

Request an Annual Quote

RNAi's Fire and Mello Win Nobel Prize in Medicine

NEW YORK (GenomeWeb News) - The Nobel Prize in Physiology or Medicine has been awarded to Andrew Fire and Craig Mello for their discovery of RNA interference, the Nobel Assembly at Sweden's Karolinska Institutet said today.
 
In 1998 Fire, a professor of pathology and genetics at the Stanford University School of Medicine, and Mello, a professor of molecular medicine at the University of Massachusetts Medical School, discovered and published the mechanism that can degrade mRNA from a specific gene.
 
While investigating how gene expression is regulated in the nematode worm, they deduced that RNAi silenced genes and can prevent certain proteins from forming. The discovery of RNAi “clarified many confusing and contradictory experimental observations and revealed a natural mechanism for controlling the flow of genetic information,” the committee said.
 
According to the Nobel Prize web site, the 2006 Nobel Prize is 10 million Swedish kronor, or $1.36 million, which Fire and Mello will share.

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.